| - GRCh37:
- ChrMT:5782-13922
- GRCh38:
- ChrMT:5782-13922
| MT-ND4L, MT-ND5, MT-TC, MT-TD, MT-TR, MT-TS1, MT-TK, MT-TL2, MT-TS2, MT-TH, MT-TY, MT-ND4, MT-TG, MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-ND3 | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:5794-14876
- GRCh38:
- ChrMT:5794-14876
| MT-CYB, MT-ND3, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-TY, MT-ATP6, MT-ATP8, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-ND6, MT-TC, MT-TD, MT-CO1, MT-CO2, MT-CO3, MT-TE, MT-TK | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:6003-11220
- GRCh38:
- ChrMT:6003-11220
| MT-TR, MT-TS1, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-TD, MT-TG, MT-TK, MT-ATP6, MT-ATP8, MT-CO1, MT-CO2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:6468-15586
- GRCh38:
- ChrMT:6468-15586
| MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-TD, MT-TE, MT-TG, MT-TH, MT-TK, MT-TL2, MT-TR, MT-TS1, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:7126-13988
- GRCh38:
- ChrMT:7126-13988
| MT-CO1, MT-CO2, MT-CO3, MT-ND3, MT-TD, MT-TG, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-ND4, MT-ND4L, MT-ND5, MT-TH, MT-TK, MT-ATP6, MT-ATP8 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:7730-11255
- GRCh38:
- ChrMT:7730-11255
| MT-CO3, MT-ND3, MT-ATP6, MT-ATP8, MT-CO2, MT-ND4, MT-ND4L, MT-TG, MT-TK, MT-TR | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8290-13040
- GRCh38:
- ChrMT:8290-13040
| MT-TR, MT-TS2, MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TK, MT-TL2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8350-13450
- GRCh38:
- ChrMT:8350-13450
| MT-TR, MT-TS2, MT-TK, MT-TL2, MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH | | Pearson syndrome | Pathogenic (Jun 12, 2019) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8470-13446
- GRCh38:
- ChrMT:8470-13446
| MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-CO3, MT-ND3, MT-ND4, MT-ATP6, MT-ATP8, MT-ND4L, MT-ND5 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8480-13440
- GRCh38:
- ChrMT:8480-13440
| MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TR, MT-TS2, MT-TG, MT-TH, MT-TL2 | | Pearson syndrome | Pathogenic (Jun 12, 2019) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8585-12965
- GRCh38:
- ChrMT:8585-12965
| MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8815-13722
- GRCh38:
- ChrMT:8815-13722
| MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8839-14895
- GRCh38:
- ChrMT:8839-14895
| MT-ATP6, MT-CO3, MT-CYB, MT-ND5, MT-ND6, MT-TE, MT-TG, MT-TS2, MT-ND3, MT-ND4, MT-ND4L, MT-TH, MT-TL2, MT-TR | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10105-15066
- GRCh38:
- ChrMT:10105-15066
| MT-CYB, MT-ND3, MT-ND4, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-ND4L, MT-ND5, MT-ND6, MT-TE | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10405
- GRCh38:
- ChrMT:10405
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10406
- GRCh38:
- ChrMT:10406
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke, Mitochondrial disease | Pathogenic/Likely pathogenic (May 4, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- ChrMT:10408
- GRCh38:
- ChrMT:10408
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely pathogenic (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10410
- GRCh38:
- ChrMT:10410
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10410
- GRCh38:
- ChrMT:10410
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10411
- GRCh38:
- ChrMT:10411
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10420
- GRCh38:
- ChrMT:10420
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10427
- GRCh38:
- ChrMT:10427
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10437
- GRCh38:
- ChrMT:10437
| MT-TR | | not specified | Uncertain significance (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10438
- GRCh38:
- ChrMT:10438
| MT-TR | | Mitochondrial disease | Pathogenic (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10440
- GRCh38:
- ChrMT:10440
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10446
- GRCh38:
- ChrMT:10446
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10448
- GRCh38:
- ChrMT:10448
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10450
- GRCh38:
- ChrMT:10450
| MT-TR | | Mitochondrial disease | Pathogenic (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10454
- GRCh38:
- ChrMT:10454
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10455
- GRCh38:
- ChrMT:10455
| MT-TR | | Mitochondrial disease | Uncertain significance (Dec 10, 2021) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:10456
- GRCh38:
- ChrMT:10456
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10457
- GRCh38:
- ChrMT:10457
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10460
- GRCh38:
- ChrMT:10460
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely pathogenic (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10462
- GRCh38:
- ChrMT:10462
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:10463
- GRCh38:
- ChrMT:10463
| MT-TR | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |